Skip to Content

Bayer AG

BAYN: XETR (DEU)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€67.00SstrbfCbjh

Undervalued Bayer Posts Mixed Q4 as Strong Crop Science Gains Expected to Partially Reverse in 2023

Bayer reported fourth-quarter earnings ahead of our expectations but issued 2023 guidance slightly below our projections, leading us to maintain our fair value estimate based on the mixed report. The weaker-than-expected 2023 guidance is likely to weigh on the stock in the near term, but we continue to view the stock as undervalued, with the market likely missing the improving long-term innovation outlook that also gives us confidence in Bayer’s wide moat.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of BAYN so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center